Have a look at this news item from Prof de Bono and the Institute of Cancer Research:
The Prof was Spurspark’s consultant and much of the testing and trialling that Spurspark was willing to put himself through (including being the first person on here to take Abbi) is benefitting current members more than they could ever imagine.
This is interesting. The drug in question is already used widely for autoimmune disease.https://www.icr.ac.uk/news-archive/immunotherapy-drug-for-skin-disease-could-boost-hormone-treatment-for-prostate-cancer
Edited by member 19 Jul 2018 at 18:24
| Reason: Not specified
It's five years old, and just the views of one man - but yes, we are living in a time of great progress, no doubt about that!
Hi Dark warrior
thanks for posting this interesting article. I completed 6 infusions of Docetaxel by August last year, however as my PSA had gone back up by Feb this year I re started a course of 10 Cabazitaxel in March. I’ve had 7 so far with no real ill effects ( still golfing, gardening, walking etc), with No 8 due on the 1st Aug. However PSA not reducing as much as when on Docetaxel so I’m off up to Bristol on Monday for a consultant clinic re-Radium 223. So it looks as if 5 years on from your article I’m following a similar path? Let’s hope it doubles my survival time too?!
Keep the Faith
Another novel approach to castration-resistant PC treatment:
This is a nice summary of bipolar androgen therapy (BAT) by Sam Denmeade, the doctor who invented it:
It's particularly interesting that in a trial for checkpoint inhibitor immunotherapy, both of the patients who responded very well had previously been through BAT. Dr Denmeade is now proposing to trial this combination. He's at Johns Hopkins in Baltimore, USA.
This recent paper shows remarkable results in metastatic PC using targeted alpha therapy, 225-Ac-PSMA.
The study was done in South Africa. I know that this treatment originated in Germany, but I don't think it's available yet in Britain, unfortunately.
Click through to become a member and gain access to support, information and real time replies.